CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 200 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04414059
NCT04414059N/ACompleted

Complications Risk Factors in Patients Hospitalized for COVID-19 Infection: Role of Proteins Electrophoresis

Elsan·observational·Posted Jun 4, 2020·Updated Oct 19, 2022

In Brief

An observational study for SARS-CoV 2 and Hospitalisation-Associated Infection. Completed, enrolled 200 participants across 2 sites.

Detailed Summary

The inflammation is central in COVID-19 infections. Our aim is to evaluate the clinical value of measuring inflammation by using serum protein electrophoresis (SPE). SPE evaluation of inflammation should be able to predict outcome, follow up evolution or treatment efficacy in patients with coronavirus infection and thus anticipate their evolution to severe viral infection and allow an optimal clinical management. SPE inflammation diagnostics will be benchmarked with other diagnostics of inflammation, currently used more routinely.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJun 4, 2020
Enrollment StartMar 10, 2021
Primary CompletionMay 10, 2022
Study CompletionSep 10, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.1 years ago